Firebrick Pharma Limited (ASX: FRE)

Market Cap	11.77M
Revenue (ttm)	2.75M
Net Income (ttm)	-1.18M
Shares Out	210.11M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,514
Open	0.0560
Previous Close	0.0540
Day's Range	0.0560 - 0.0560
52-Week Range	0.0450 - 0.1100
Beta	1.68
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FRE

Financial Performance

In 2024, Firebrick Pharma's revenue was 2.75 million, an increase of 12096.48% compared to the previous year's 22,550. Losses were -1.18 million, -82.71% less than in 2023.